Skip to content

MOLN

Molecular Partners AG

NASDAQ · Healthcare · Biotechnology · CH

$3.20
+3.40%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+16.1%
EBIT
+15.5%
EPS
+18.8%
Free cash flow
+13.1%
Operating cash flow
+12.3%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
-6.0%

Three-year CAGR

Revenue
-100.0%
EBITDA
-15.2%
EBIT
+5.1%
Net income
-14.1%
EPS
-3.8%
Free cash flow
+13.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026